New Cannabis-Derived Compound Offers Pain Relief Without the Side Effects

For years now, North America has been dealing with a crisis stemming from opioid use.  In 2022 alone, there were over 82,000 deaths attributed to the drug class in the United States.  While they remain remarkably effective at managing pain, it has become clear that an alternative is needed.  To that end, researchers have been doggedly seeking other solutions that can offer most of the pain relief that opioids can but, importantly, without the terrible levels of addiction and deaths that follow.  Thankfully, progress is being made on this front, with the most recent example coming from a joint effort out of Washington University School of Medicine and Stanford University.

Titled ‘A cryptic pocket in CB1 drives peripheral and functional selectivity’,¹ this study unveiled a promising breakthrough — a custom-designed cannabinoid compound that provides pain relief without affecting the brain or inducing addiction.

Details of the Study

Through past articles here at mycannabis.com, we have highlighted how cannabis has been used for millennia to alleviate pain.  In modern society, though, its psychoactive effects, which are primarily controlled by cannabinoid receptor one (CB1) in the brain, have prevented it from becoming a widely accepted medical treatment.  Until now, clinical trials may have explored its efficacy for chronic pain, but concerns over cognitive impairment and addiction have slowed broader adoption.

In this latest research, the team aimed to develop/engineer a modified cannabinoid molecule with a key distinction: it cannot cross the blood-brain barrier.  This means that while the molecule can activate CB1 receptors in pain-sensing nerve cells throughout the body, it does not reach brain cells, thereby avoiding psychoactive effects and addiction potential.

How the Compound Works

Traditional opioids work by binding to receptors in the brain and spinal cord, dulling the sensation of pain.  An unfortunate side-effect is that alongside doing so, the brain also sees its reward system triggered in such a way that a flood of dopamine is released, which leads to addictive behaviors.

The new compound was chemically engineered with a positive charge, preventing it from entering the brain but allowing it to engage CB1 receptors outside the central nervous system.  In doing so, it reduces the perception of pain effectively while avoiding cognitive impairment or addiction.  Simply put, by modifying the molecular structure, researchers ensured that the compound selectively targets pain-sensing nerve cells without influencing mood or mental clarity.

Animal Models

It should be noted that the effectiveness of the compound was tested on models of chronic pain in mice that included nerve injury pain and migraine headaches.  The researchers assessed pain levels by measuring touch hypersensitivity—a common metric in pain studies.  In both models, the administration of the new cannabinoid compound significantly reduced pain responses, demonstrating its analgesic potential.

One of the most striking findings from the study was the absence of tolerance buildup.  Many pain medications, including opioids, become less effective over time as the body develops tolerance, necessitating higher doses for the same relief.  However, in mice that received the modified cannabinoid compound twice daily over nine days, no signs of tolerance emerged.  This suggests that the drug could be a viable long-term pain management solution without the risk of escalating dosages.

An Unexpected Discovery

The study’s success also stemmed from an unexpected discovery involving a previously unknown binding pocket on the CB1 receptor.  Once thought to be inaccessible to cannabinoids, it was found that the pocket intermittently opens, allowing the modified compound to bind, which reduces the cellular activity that typically leads to drug tolerance.

By leveraging this hidden pocket, the researchers created a drug that provides sustained pain relief without the need for increasing doses over time.  When looked at as a whole, these findings have the potential to result in the creation of a medication that can effectively target chronic pain without the risk of addiction.

A Potential Solution to the Opioid Crisis?

While it will take much more than this potential medication to solve the opioid crisis, it is a great start to solving a difficult problem.  As it stands, there has been a disconnect between chronic pain patients and their doctors for years—patients often feel their pain is inadequately managed, while doctors struggle to balance effective pain relief with the risks of opioid addiction.  Cannabis, with its multifaceted pain-relieving properties and lower addiction risk, could help bridge this gap.

Moreover, growing evidence suggests that cannabis may not serve as a gateway drug but rather as an opioid substitute, potentially reducing opioid dependency among chronic pain patients.  The misconception that cannabis use inevitably leads to harder drugs has been a historical barrier to its acceptance as a legitimate medicine, but research continues to challenge that outdated notion.

The next phase of research involves refining the compound into an oral medication suitable for human use.  Given its promising results in animal models, the team hopes to transition to clinical trials to evaluate safety, efficacy, and dosage optimization in humans.

Studies Referenced:

^{1. Rangari, V.A., O’Brien, E.S., Powers, A.S. et al. A cryptic pocket in CB1 drives peripheral and functional selectivity. Nature (2025). https://doi.org/10.1038/s41586-025-08618-7}